Table 2. Distribution of CTLA4 according to clinico-pathologic factors.

Characteristics	Total	CTLA4 0, n (%)	CTLA4 I, n (%)	CTLA II, n (%)	CTLA III, n (%)	P value
Age, years	222					0.747
≤50		13 (13.0)	24 (24.0)	40 (40.0)	23 (23.0)
>50		15 (12.3)	35 (28.7)	41 (33.6)	31 (25.4)
Menstrual status	220					0.928
Pre-menopause		12 (12.4)	27 (27.8)	37 (38.1)	21 (21.6)
Post-menopause		16 (13.0)	32 (26.0)	44 (35.8)	31 (25.2)
Pathology	222					0.822
IDC		25 (13.3)	51 (27.1)	67 (35.6)	45 (23.9)
Others		3 (8.8)	8 (23.5)	14 (41.2)	9 (26.5)
PG	212					0.03
I		4 (40.0)	2 (20.0)	3 (30.0)	1 (10.0)
II		20 (15.9)	40 (31.7)	44 (34.9)	22 (17.5)
III		3 (3.9)	17 (22.4)	30 (39.5)	26 (34.2)
T stage	216					0.00
T1		19 (23.5)	29 (35.8)	26 (32.1)	7 (8.6)
T2–3		9 (6.7)	27 (20.0)	53 (39.3)	46 (34.1)
N stage	222					0.051
N0		21 (17.6)	35 (29.4)	43 (36.1)	20 (16.8)
N1		3 (5.7)	11 (20.8)	21 (39.6)	18 (34.0)
N2–3		4 (8.0)	13 (26.0)	17 (34.0)	16 (32.0)
Ki-67 index	210					0.02
<20		19 (17.1)	31 (27.9)	45 (40.5)	16 (14.4)
≥20		8 (8.1)	23 (23.2)	32 (32.3)	36 (36.4)
Subtype	219					0.000
Luminal		23 (14.4)	50 (31.3)	62 (38.8)	25 (15.6)
Her2		1 (7.1)	1 (7.1)	7 (50.0)	5 (35.7)
TNBC		2 (4.4)	8 (17.8)	12 (26.7)	23 (51.1)
Therapy	221					0.270
No		5 (22.7)	3 (13.6)	9 (40.9)	5 (22.7)
Yes		22 (11.1)	56 (28.1)	72 (36.2)	49 (24.6)